Urine cytology in the evaluation of urological malignancy revisited: is it still necessary?
Affiliation
Department of Urology, Mercy University Hospital, Glenville Place, Cork, Ireland., opefaleb@yahoo.comIssue Date
2012-01-31T16:38:51ZMeSH
AgedAged, 80 and over
Carcinoma, Transitional Cell/pathology
Cystoscopy/methods
False Positive Reactions
Female
Hematuria/pathology
Humans
Male
Middle Aged
Sensitivity and Specificity
Urinary Bladder Neoplasms/*pathology/urine
Urology/*methods
Metadata
Show full item recordCitation
Urol Int. 2010;84(1):45-9. Epub 2010 Feb 17.Journal
Urologia internationalisDOI
10.1159/000273465PubMed ID
20173368Abstract
OBJECTIVE: We aim to determine if urine cytology was still necessary as a routine part of the evaluation for the presence of urological malignancy and to evaluate its cost effectiveness. METHODS: Urine cytology reports over a 6-year period (2000-2005) were retrieved from our institution's pathology department database. Patients with urine cytology positive for malignant cells were identified. We retrospectively reviewed the charts of these patients for age, sex, flexible cystoscopy and radiological imaging results. The cost of urine cytology was retrieved from the pathology department. RESULTS: There were a total of 2,568 urine cytological examinations. Of these, 25 were positive for malignant cells. There were 19 male (76%) and 6 female (24%) patients with a mean age of 72 years (range: 49-97). In 21 patients with positive cytology, a bladder tumor was identified at flexible cystoscopy and/or imaging studies. For a positive cytology yield of 1%, EUR 210,000 was spent. CONCLUSIONS: Routine urine cytology was not cost effective and did not add to the diagnostic yield beyond cystoscopy and diagnostic imaging. It may be omitted in the initial evaluation of urological malignancy.Language
engISSN
1423-0399 (Electronic)0042-1138 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1159/000273465
Scopus Count
Collections
Related articles
- Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
- Authors: Kumar A, Kumar R, Gupta NP
- Issue date: 2006 Mar
- Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
- Authors: Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A
- Issue date: 2002 Aug
- Urine cytology after flexible cystoscopy.
- Authors: Herr HW, Regan M
- Issue date: 2005 Oct
- [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
- Authors: Fernández Gómez JM, García Rodríguez J, Escaf Barmadah S, Raigoso P, Rodríguez Martínez JJ, Allende MT, Casasola Chamorro J, Rodríguez Faba O, Martín Benito JL, Regadera Sejas FJ
- Issue date: 2002 Jan-Feb
- Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
- Authors: Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ
- Issue date: 2000